Who are Temozolomide and lomustine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/temozolomide-and-lomustine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Temozolomide and lomustine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide and lomustine (Temozolomide and lomustine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent (nitrosourea combination). Area: Oncology.

phase 3 Alkylating agent (nitrosourea combination) DNA (O6-guanine methylation) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Temozolomide and lomustine (Temozolomide and lomustine) — University Hospital, Bonn. Temozolomide and lomustine are alkylating agents that cross the blood-brain barrier and cause DNA damage to kill cancer cells, particularly effective in brain tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Temozolomide and lomustine TARGET	Temozolomide and lomustine	University Hospital, Bonn	phase 3	Alkylating agent (nitrosourea combination)	DNA (O6-guanine methylation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent (nitrosourea combination) class)

University Hospital, Bonn · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Temozolomide and lomustine — Competitive Intelligence Brief. https://druglandscape.com/ci/temozolomide-and-lomustine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing